A Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-Week Maintenance Phase in Patients With Early Parkinsons Disease (PD).

Trial Profile

A Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-Week Maintenance Phase in Patients With Early Parkinsons Disease (PD).

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2011 New source identified and integrated (European Clinical Trials Database).
    • 28 Jul 2010 Results published in Movement Disorders.
    • 22 Feb 2010 FDA has approved once-daily MIRAPEX ER for the treatment of early parkinson's disease, according to a Boehringer Ingelheim media release. The FDA approval was supported by this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top